General Western Blot Reagents
Abcam BHHCT, Fluorescent sensitizer for Eu3+- labelling, 1G
MW 804.9 Da, Purity >90%. Fluorescent sensitizer for Eu3+- labelling. Increases luminescence intensity 11 fold. Persists as an Eu3+ complex for 500 μs typical of the Eu3+ oxidation state. Measures peroxidase activity and oxidative stress levels.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Rhodamine 6G bis(o x yethylamino)ethane amide bis(trifluoroacetate), Fluorescent labeling rhodamine, 250MG
MW 772.73 g/mol, Purity >95%. Fluorescent labeling rhodamine for proteomics research. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Antibiotic PF 1052, Neutrophil migration inhibitor, 1MG
MW 429.59 g/mol, Purity >98%. Neutrophil migration inhibitor. Antibacterial and potentially antifungal and phytotoxic properties. Active in vivo and in vitro. See similar compound
The product is subject to the following: Abcam Restricted Use Statement
Abcam Fascaplysin, ATP-competitve CDK4 inhibitor, 1MG
MW 306.75 g/mol. Potent, selective ATP-competitive CDK4 inhibitor (IC₅₀ = 350 nM). Suppresses VEGF expression and inhibits endothelial cell proliferation. Induces apoptosis and cytotoxic autophagy in vitro.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Bisindolylmaleimide x I hydrochloride, PKC inhibitor, 1MG
MW 489 Da, Purity >98%. Selective, cell-permeable protein kinase C (PKC) inhibitor that displays 10-fold greater selectivity for PKCα (IC₅₀ = 9 nM) and 4-fold greater selectivity for PKCβI (IC₅₀ = 28 nM) over Ca²+-independent PKCε (IC₅₀ = 108 nM). Enhances cardiac contractility and protection from heart failure. Prevents T-cell activation and proliferation (IC₅₀s ranging from 30-150 nM) associated with chronic inflammatory responses in vivo. Also inhibits GRK2, GRK5, and GRK6 (IC₅₀ values are 29, 3.6, and 16 μM, respectively).
The product is subject to the following: Abcam Restricted Use Statement
Abcam Phortress, Antitumor agent, 50MG
MW 459.4 Da, Purity >98%. Potent antitumor agent (IC₅₀ values for MCF-7 and MDA468 cells are 40 nM and 158 nM, respectively). Active against breast, ovarian and renal carcinomas. Taken up into sensitive cells followed by aryl hydrocarbon receptor binding and translocation into the nucleus. Requires metabolic activation by cytochrome P450 to generate cytotoxic species. Active in vitro and in vivo. Water soluble.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Calcitriol, Vitamin D receptor (VDR) agonist, 250UG
MW 416.6 Da, Purity >99%. Calcitriol, Vitamin D receptor (VDR) agonist. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Chloramphenicol, antibiotic agent, 5G
MW 323.13 Da, Purity >99%. Broad spectrum antibiotic agent. Binds selectively to A2451 and A2452 residues in the 23S rRNA of the 50S ribosomal subunit. Prevents peptide bond formation and protein chain elongation inhibiting protein biosynthesis. Shows bacteriostatic effects against a wide variety of Gram-positive and Gram-negative bacteria in vivo. Orally active.
The product is subject to the following: Abcam Restricted Use Statement
Abcam 4-Aminophenyl phosphate monosodium salt, Alkaline phosphatase substrate, 10MG
MW 211.09 Da, Purity >99%. Substrate for electrochemical alkaline phosphatase measurement. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam RGD (Arg-Gly-Asp), sequence involved in cell adhesion, 25MG
MW 346.34 Da, Purity >95%. RGD (Arg-Gly-Asp), sequence involved in cell adhesion. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam WY 14643, PPARalpha agonist, 10MG
MW 323.8 g/mol, Purity >99%. Selective PPARα agonist (EC₅₀ values are 0.63, 32 and >100 μM at PPARα, PPARγ and PPARδ receptors respectively). Able to reduce inflammatory responses in vivo and in vitro.
The product is subject to the following: Abcam Restricted Use Statement
Abcam O x aliplatin, Platinum anticancer agent, 50MG
MW 397.29 g/mol, Purity >99%. Diaminocyclohexane platinum anticancer agent. Induces DNA cross-linking and blocks DNA synthesis. Induces apoptosis and cell cycle arrest.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Aeroplysinin (Aeroplysinin-1), antiangiogenic agent, 100UG
MW 338.98 Da, Purity >95%. Potent antiangiogenic agent. Inhibits COX-2 expression. Selectivity for endothelial cells. Able to induce apoptosis via capsase activation, chromatin condensation and nuclear fragmentation. Antibiotic and cytotoxic effects (IC₅₀ = 3 μm) and displays a wide-spectrum antitumor activity. Active in vivo. .
The product is subject to the following: Abcam Restricted Use Statement
Abcam Prostratin, PKC activator, 500UG
MW 390.48 g/mol. PKC activator; reactivates HIV-1 latency (IC₅₀ = ~0.5 μM) by PKC dependent NF-κB activation. Downregulates expression of HIV-1 receptor CD4 and its co-receptors CXCR4 and CCR5 in vitro. Non-tumor promoting.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Fluconazole, Cytochrome P450 inhibitor, 50MG
MW 306.27 Da, Purity >99%. Triazole antifungal agent. Cytochrome P450 inhibitor (IC₅₀ values are 30.3, 12.3, 13.1 μM for CYP2C9, CYP2C19 and CYP3A4, respectively). Penetrates the blood-brain barrier.
The product is subject to the following: Abcam Restricted Use Statement